2022 World Conference on Lung Cancer (ePosters)-EP05.01-032. The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC

EP05.01-032. The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC

Back to course

Pdf Summary

This study aimed to evaluate the effects of durvalumab on brain metastasis and radiation pneumonitis in patients with unresectable stage III non-small cell lung cancer (NSCLC) who received chemoradiotherapy. The study collected data from 115 patients from six affiliated hospitals. The patients were divided into two groups: the concurrent chemoradiation (CCRT) group (60 patients) and the CCRT-Durvalumab group (55 patients). <br /><br />The study found that the incidence of new brain metastasis was lower in the durvalumab group compared to the placebo group. Brain metastasis in lung cancer has a poor prognosis, with a median survival of 1-3 months in untreated patients. The study also evaluated the incidence of symptomatic radiation pneumonitis, which can be life-threatening. <br /><br />The results showed that symptomatic radiation pneumonitis occurred more frequently in the durvalumab group, but the difference was not significant. No severe grade 4-5 pneumonitis was observed in the durvalumab group. <br /><br />The overall survival rate and progression-free survival rate were significantly improved in the durvalumab group compared to the CCRT group. However, longer follow-up duration is required to confirm the brain progression and central nervous system activity in the durvalumab group. <br /><br />In conclusion, durvalumab may help suppress brain metastasis with an earlier onset but limited progression in patients with unresectable stage III NSCLC who received chemoradiotherapy. The incidence of symptomatic radiation pneumonitis was more frequent in the durvalumab group, but not significantly different. Overall survival and progression-free survival were significantly improved in the durvalumab group in a real-world clinical setting. Further evaluations and longer follow-up are needed to confirm the findings.

Asset Subtitle

YeonSil Kim

Meta Tag

Speaker YeonSil Kim

Topic Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

Keywords

durvalumab

brain metastasis

radiation pneumonitis

non-small cell lung cancer

chemoradiotherapy

concurrent chemoradiation

placebo group

symptomatic radiation pneumonitis

overall survival rate

progression-free survival rate